Book
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 156 - 163
Summary Background Patients with isolated locoregional recurrences (ILRR) of breast cancer have a high risk of distant metastasis and death from breast cancer....
Hematology, Oncology and Palliative Medicine | MASTECTOMY | TUMOR RECURRENCE | SURGICAL ADJUVANT BREAST | LOCAL RECURRENCE | ONCOLOGY | PROGNOSIS | CONSERVING SURGERY | TAMOXIFEN | METASTASES | RECEPTOR CONVERSION | RADIATION-THERAPY | South America | Breast Neoplasms - surgery | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - surgery | North America | Patient Selection | Neoplasm Recurrence, Local - pathology | Breast Neoplasms - chemistry | Time Factors | Mastectomy, Segmental | Mastectomy | Female | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Biomarkers, Tumor - analysis | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Breast Neoplasms - drug therapy | Neoplasm Recurrence, Local - chemistry | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Breast Neoplasms - mortality | South Africa | Australia | Medical colleges | Relapse | Chemotherapy | Breast cancer | Public health | Diseases | Cancer
Hematology, Oncology and Palliative Medicine | MASTECTOMY | TUMOR RECURRENCE | SURGICAL ADJUVANT BREAST | LOCAL RECURRENCE | ONCOLOGY | PROGNOSIS | CONSERVING SURGERY | TAMOXIFEN | METASTASES | RECEPTOR CONVERSION | RADIATION-THERAPY | South America | Breast Neoplasms - surgery | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - surgery | North America | Patient Selection | Neoplasm Recurrence, Local - pathology | Breast Neoplasms - chemistry | Time Factors | Mastectomy, Segmental | Mastectomy | Female | Chemotherapy, Adjuvant | Radiotherapy, Adjuvant | Biomarkers, Tumor - analysis | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Breast Neoplasms - drug therapy | Neoplasm Recurrence, Local - chemistry | Disease Progression | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Breast Neoplasms - mortality | South Africa | Australia | Medical colleges | Relapse | Chemotherapy | Breast cancer | Public health | Diseases | Cancer
Journal Article
Annals of Surgery, ISSN 0003-4932, 05/2018, Volume 267, Issue 5, pp. 936 - 945
OBJECTIVE:To describe accurately the pattern, timing, and predictors of disease recurrence after a potentially curative resection for pancreatic ductal...
predictors for recurrence | recurrence location | recurrence-free survival | cancer recurrence | pancreatectomy | pancreatic ductal adenocarcinoma | SURGERY | PROGNOSTIC-FACTORS | LONG-TERM SURVIVAL | CURATIVE RESECTION | 5-YEAR SURVIVORS | CHEMORADIOTHERAPY | THERAPY | PROSTATE-CANCER | BRAIN-METASTASIS | CARCINOMA | ISOLATED LOCAL RECURRENCE
predictors for recurrence | recurrence location | recurrence-free survival | cancer recurrence | pancreatectomy | pancreatic ductal adenocarcinoma | SURGERY | PROGNOSTIC-FACTORS | LONG-TERM SURVIVAL | CURATIVE RESECTION | 5-YEAR SURVIVORS | CHEMORADIOTHERAPY | THERAPY | PROSTATE-CANCER | BRAIN-METASTASIS | CARCINOMA | ISOLATED LOCAL RECURRENCE
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 3/2014, Volume 21, Issue 3, pp. 717 - 730
There is no consensus on what constitutes adequate negative margins in breast-conserving therapy (BCT). We systematically review the evidence on surgical...
Oncology | Medicine & Public Health | Surgical Oncology | Surgery | SURGERY | DOSE-ESCALATION | TUMOR RECURRENCE | DEFINITIVE IRRADIATION | RISK-FACTORS | ONCOLOGY | POSITIVE MARGINS | DISTANT METASTASES | 20-YEAR FOLLOW-UP | LOCOREGIONAL RECURRENCE | CONSERVATION THERAPY | RADIATION-THERAPY | Neoplasm, Residual - pathology | Breast Neoplasms - surgery | Neoplasm, Residual - etiology | Prognosis | Neoplasm Invasiveness | Humans | Mastectomy, Segmental - adverse effects | Neoplasm Recurrence, Local - etiology | Neoplasm Recurrence, Local - pathology | Breast Neoplasms - pathology | Female | Neoplasm Staging | Postoperative Complications | Women | Lumpectomy | Medical colleges | Relapse | Analysis | Breast cancer | Diseases | meta-analysis | margins | breast cancer | local recurrence | breast-conserving therapy
Oncology | Medicine & Public Health | Surgical Oncology | Surgery | SURGERY | DOSE-ESCALATION | TUMOR RECURRENCE | DEFINITIVE IRRADIATION | RISK-FACTORS | ONCOLOGY | POSITIVE MARGINS | DISTANT METASTASES | 20-YEAR FOLLOW-UP | LOCOREGIONAL RECURRENCE | CONSERVATION THERAPY | RADIATION-THERAPY | Neoplasm, Residual - pathology | Breast Neoplasms - surgery | Neoplasm, Residual - etiology | Prognosis | Neoplasm Invasiveness | Humans | Mastectomy, Segmental - adverse effects | Neoplasm Recurrence, Local - etiology | Neoplasm Recurrence, Local - pathology | Breast Neoplasms - pathology | Female | Neoplasm Staging | Postoperative Complications | Women | Lumpectomy | Medical colleges | Relapse | Analysis | Breast cancer | Diseases | meta-analysis | margins | breast cancer | local recurrence | breast-conserving therapy
Journal Article
BJU International, ISSN 1464-4096, 11/2013, Volume 112, Issue 7, pp. 909 - 916
Objectives To assess the prognostic impact of time to recurrence (TTR) on cancer‐specific survival (CSS) after recurrence in patients with renal cell carcinoma...
renal cell carcinoma (RCC) | time to recurrence | early recurrence | nephrectomy | prognostic parameters | late recurrence | cancer‐specific survival | cancer-specific survival | GUIDELINES | ALGORITHM | MODEL | FUNCTIONAL FORM | CLINICAL-TRIALS | SURVEILLANCE | UROLOGY & NEPHROLOGY | KIDNEY CANCER | Prognosis | Humans | Middle Aged | Carcinoma, Renal Cell - surgery | Male | Survival Rate | Kidney Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Carcinoma, Renal Cell - mortality | Kidney Neoplasms - surgery | Time Factors | Female | Aged | Retrospective Studies | Databases, Factual | Relapse | Patient outcomes | Cancer | Diseases | Medical research | Surgery | Gender
renal cell carcinoma (RCC) | time to recurrence | early recurrence | nephrectomy | prognostic parameters | late recurrence | cancer‐specific survival | cancer-specific survival | GUIDELINES | ALGORITHM | MODEL | FUNCTIONAL FORM | CLINICAL-TRIALS | SURVEILLANCE | UROLOGY & NEPHROLOGY | KIDNEY CANCER | Prognosis | Humans | Middle Aged | Carcinoma, Renal Cell - surgery | Male | Survival Rate | Kidney Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Carcinoma, Renal Cell - mortality | Kidney Neoplasms - surgery | Time Factors | Female | Aged | Retrospective Studies | Databases, Factual | Relapse | Patient outcomes | Cancer | Diseases | Medical research | Surgery | Gender
Journal Article
Journal of Urology, The, ISSN 0022-5347, 2015, Volume 194, Issue 2, pp. 316 - 322
Purpose Isolated local retroperitoneal recurrence after radical nephrectomy for renal cell carcinoma poses a therapeutic challenge. We investigated outcomes in...
Urology | kidney | renal cell | lymph nodes | carcinoma | neoplasm recurrence | nephrectomy | local | RESECTION | NATURAL-HISTORY | FOSSA RECURRENCE | INTERFERON-ALPHA | THERAPY | UROLOGY & NEPHROLOGY | OUTCOMES | neoplasm recurrence, local | carcinoma, renal cell | KIDNEY CANCER | Follow-Up Studies | Humans | Middle Aged | Carcinoma, Renal Cell - surgery | Male | Neoplasm Recurrence, Local - surgery | Incidence | Kidney Neoplasms - surgery | Retroperitoneal Neoplasms - mortality | Nephrectomy | Female | Retrospective Studies | Retroperitoneal Neoplasms - surgery | Retroperitoneal Neoplasms - secondary | Texas - epidemiology | Reoperation | Survival Rate - trends | Treatment Outcome | Kidney Neoplasms - mortality | Carcinoma, Renal Cell - mortality | Disease-Free Survival | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - pathology | Neoplasm Recurrence, Local - epidemiology | Neoplasm Staging | renal cell carcinoma | radical nephrectomy | adrenal | renal fossa | lymph node | local recurrence | retroperitoneal recurrence
Urology | kidney | renal cell | lymph nodes | carcinoma | neoplasm recurrence | nephrectomy | local | RESECTION | NATURAL-HISTORY | FOSSA RECURRENCE | INTERFERON-ALPHA | THERAPY | UROLOGY & NEPHROLOGY | OUTCOMES | neoplasm recurrence, local | carcinoma, renal cell | KIDNEY CANCER | Follow-Up Studies | Humans | Middle Aged | Carcinoma, Renal Cell - surgery | Male | Neoplasm Recurrence, Local - surgery | Incidence | Kidney Neoplasms - surgery | Retroperitoneal Neoplasms - mortality | Nephrectomy | Female | Retrospective Studies | Retroperitoneal Neoplasms - surgery | Retroperitoneal Neoplasms - secondary | Texas - epidemiology | Reoperation | Survival Rate - trends | Treatment Outcome | Kidney Neoplasms - mortality | Carcinoma, Renal Cell - mortality | Disease-Free Survival | Carcinoma, Renal Cell - secondary | Kidney Neoplasms - pathology | Neoplasm Recurrence, Local - epidemiology | Neoplasm Staging | renal cell carcinoma | radical nephrectomy | adrenal | renal fossa | lymph node | local recurrence | retroperitoneal recurrence
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 747 - 756
Summary Background How best to treat rising prostate-specific antigen (PSA) concentration after radical prostatectomy is an urgent clinical question. Salvage...
Hematology, Oncology and Palliative Medicine | ANDROGEN DEPRIVATION | ONCOLOGY | BIOCHEMICAL RECURRENCE | FOLLOW-UP | RISK | NATURAL-HISTORY | CANCER | PROGRESSION | RADIATION-THERAPY | PSA | ADJUVANT | Neoplasm Recurrence, Local - radiotherapy | Prostatic Neoplasms - radiotherapy | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - surgery | Aged, 80 and over | Prostatic Neoplasms - blood | Neoplasm Recurrence, Local - blood | Prostatic Neoplasms - drug therapy | Adenocarcinoma - radiotherapy | Prostatic Neoplasms - surgery | Adenocarcinoma - blood | Survival Rate | Combined Modality Therapy | Adenocarcinoma - drug therapy | Prostate-Specific Antigen - blood | Biomarkers, Tumor - blood | Androgen Antagonists - therapeutic use | Radiotherapy, Conformal | Prostatectomy | Aged | Neoplasm Staging | Adenocarcinoma - surgery | Radiotherapy | Antigens | Surgery | Life Sciences | Cancer
Hematology, Oncology and Palliative Medicine | ANDROGEN DEPRIVATION | ONCOLOGY | BIOCHEMICAL RECURRENCE | FOLLOW-UP | RISK | NATURAL-HISTORY | CANCER | PROGRESSION | RADIATION-THERAPY | PSA | ADJUVANT | Neoplasm Recurrence, Local - radiotherapy | Prostatic Neoplasms - radiotherapy | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Male | Neoplasm Recurrence, Local - surgery | Aged, 80 and over | Prostatic Neoplasms - blood | Neoplasm Recurrence, Local - blood | Prostatic Neoplasms - drug therapy | Adenocarcinoma - radiotherapy | Prostatic Neoplasms - surgery | Adenocarcinoma - blood | Survival Rate | Combined Modality Therapy | Adenocarcinoma - drug therapy | Prostate-Specific Antigen - blood | Biomarkers, Tumor - blood | Androgen Antagonists - therapeutic use | Radiotherapy, Conformal | Prostatectomy | Aged | Neoplasm Staging | Adenocarcinoma - surgery | Radiotherapy | Antigens | Surgery | Life Sciences | Cancer
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 82, Issue 3, pp. 1185 - 1191
Purpose To determine whether breast cancer subtype is associated with patterns of ipsilateral breast tumor recurrence (IBTR), either true recurrence (TR) or...
Radiology | Hematology, Oncology and Palliative Medicine | Basal | Biologic subtype | True recurrence | Triple negative | Local recurrence | Breast cancer | Elsewhere local recurrence | ADJUVANT CHEMOTHERAPY | TUMOR RECURRENCE | STAGE-I | CONSERVATIVE SURGERY | 20-YEAR FOLLOW-UP | ESTROGEN-RECEPTOR | RADIATION-THERAPY | DISTANT RECURRENCE | ONCOLOGY | PROGESTERONE-RECEPTOR | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Multivariate Analysis | Receptors, Estrogen - metabolism | Age Factors | Follow-Up Studies | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Risk | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Breast Neoplasms - therapy | Neoplasm Recurrence, Local - pathology | Young Adult | Receptor, Epidermal Growth Factor - metabolism | Neoplasm Grading | Mastectomy, Segmental | Aged, 80 and over | Adult | Female | Radiotherapy Dosage | Neoplasm Recurrence, Local - metabolism | Tumor Burden | Breast Neoplasms - pathology | Aged | Neoplasm Staging | Lumpectomy | Care and treatment | Nuclear radiation | Cancer | ESTROGENS | DIAGNOSIS | PATIENTS | MAMMARY GLANDS | NEOPLASMS | PROGESTERONE | RADIATION DOSES | PATHOLOGY | CHEMOTHERAPY | GROWTH FACTORS | MULTIVARIATE ANALYSIS | WOMEN | TETRAGONAL LATTICES | RADIOLOGY AND NUCLEAR MEDICINE | RECEPTORS | HAZARDS | triple negative | breast cancer | local recurrence | biologic subtype | true recurrence | basal | elsewhere recurrence
Radiology | Hematology, Oncology and Palliative Medicine | Basal | Biologic subtype | True recurrence | Triple negative | Local recurrence | Breast cancer | Elsewhere local recurrence | ADJUVANT CHEMOTHERAPY | TUMOR RECURRENCE | STAGE-I | CONSERVATIVE SURGERY | 20-YEAR FOLLOW-UP | ESTROGEN-RECEPTOR | RADIATION-THERAPY | DISTANT RECURRENCE | ONCOLOGY | PROGESTERONE-RECEPTOR | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Multivariate Analysis | Receptors, Estrogen - metabolism | Age Factors | Follow-Up Studies | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Risk | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Breast Neoplasms - therapy | Neoplasm Recurrence, Local - pathology | Young Adult | Receptor, Epidermal Growth Factor - metabolism | Neoplasm Grading | Mastectomy, Segmental | Aged, 80 and over | Adult | Female | Radiotherapy Dosage | Neoplasm Recurrence, Local - metabolism | Tumor Burden | Breast Neoplasms - pathology | Aged | Neoplasm Staging | Lumpectomy | Care and treatment | Nuclear radiation | Cancer | ESTROGENS | DIAGNOSIS | PATIENTS | MAMMARY GLANDS | NEOPLASMS | PROGESTERONE | RADIATION DOSES | PATHOLOGY | CHEMOTHERAPY | GROWTH FACTORS | MULTIVARIATE ANALYSIS | WOMEN | TETRAGONAL LATTICES | RADIOLOGY AND NUCLEAR MEDICINE | RECEPTORS | HAZARDS | triple negative | breast cancer | local recurrence | biologic subtype | true recurrence | basal | elsewhere recurrence
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1200 - 1207
Summary Background Recurrent medulloblastoma is a therapeutic challenge because it is almost always fatal. Studies have confirmed that medulloblastoma consists...
Hematology, Oncology and Palliative Medicine | EVOLUTION | ONCOLOGY | PROGNOSIS | ADOLESCENTS | INTRATUMOR HETEROGENEITY | DISTINCT | ABERRATIONS | CANCER | CHEMOTHERAPY | PROGRESSION | CHILDREN | Medulloblastoma - secondary | Prognosis | United States | Humans | Child, Preschool | Male | Medulloblastoma - therapy | Medulloblastoma - mortality | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - pathology | Time Factors | Female | Retrospective Studies | Cerebellar Neoplasms - pathology | Cerebellar Neoplasms - classification | Medulloblastoma - genetics | Child | Principal Component Analysis | Genetic Predisposition to Disease | Europe | Neoplasm Recurrence, Local - therapy | Risk Factors | Cerebellar Neoplasms - mortality | Kaplan-Meier Estimate | Cerebellar Neoplasms - genetics | Neoplasm Recurrence, Local - classification | Canada | Phenotype | Adolescent | Neoplasm Recurrence, Local - genetics | Cerebellar Neoplasms - therapy | Medulloblastoma - classification | Gliomas
Hematology, Oncology and Palliative Medicine | EVOLUTION | ONCOLOGY | PROGNOSIS | ADOLESCENTS | INTRATUMOR HETEROGENEITY | DISTINCT | ABERRATIONS | CANCER | CHEMOTHERAPY | PROGRESSION | CHILDREN | Medulloblastoma - secondary | Prognosis | United States | Humans | Child, Preschool | Male | Medulloblastoma - therapy | Medulloblastoma - mortality | Neoplasm Recurrence, Local - mortality | Neoplasm Recurrence, Local - pathology | Time Factors | Female | Retrospective Studies | Cerebellar Neoplasms - pathology | Cerebellar Neoplasms - classification | Medulloblastoma - genetics | Child | Principal Component Analysis | Genetic Predisposition to Disease | Europe | Neoplasm Recurrence, Local - therapy | Risk Factors | Cerebellar Neoplasms - mortality | Kaplan-Meier Estimate | Cerebellar Neoplasms - genetics | Neoplasm Recurrence, Local - classification | Canada | Phenotype | Adolescent | Neoplasm Recurrence, Local - genetics | Cerebellar Neoplasms - therapy | Medulloblastoma - classification | Gliomas
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 12/2014, Volume 148, Issue 3, pp. 599 - 613
The 70-gene signature (MammaPrint™) has been developed to predict the risk of distant metastases in breast cancer and select those patients who may benefit...
70-gene signature | Medicine & Public Health | Radiation oncology | Surgery | Oncology | Risk prediction | Breast cancer | Locoregional recurrence | SURVIVAL | WOMEN | 70-GENE PROGNOSIS-SIGNATURE | LOCAL RECURRENCE | ONCOLOGY | VALIDATION | Breast Neoplasms - surgery | Neoplasm Recurrence, Local - radiotherapy | Prognosis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Neoplasm Recurrence, Local - drug therapy | Gene Expression Profiling | Neoplasm Recurrence, Local - surgery | Neoplasm Recurrence, Local - pathology | Netherlands | Adult | Female | Radiotherapy, Adjuvant | Neoplasm Proteins - biosynthesis | Risk Factors | Lymphatic Metastasis | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - radiotherapy | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | Lumpectomy | Chemotherapy | Relapse | Genes | Genetic research | Genetic aspects | Gene expression | Health aspects | Cancer | Diseases
70-gene signature | Medicine & Public Health | Radiation oncology | Surgery | Oncology | Risk prediction | Breast cancer | Locoregional recurrence | SURVIVAL | WOMEN | 70-GENE PROGNOSIS-SIGNATURE | LOCAL RECURRENCE | ONCOLOGY | VALIDATION | Breast Neoplasms - surgery | Neoplasm Recurrence, Local - radiotherapy | Prognosis | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Neoplasm Recurrence, Local - drug therapy | Gene Expression Profiling | Neoplasm Recurrence, Local - surgery | Neoplasm Recurrence, Local - pathology | Netherlands | Adult | Female | Radiotherapy, Adjuvant | Neoplasm Proteins - biosynthesis | Risk Factors | Lymphatic Metastasis | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - radiotherapy | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | Lumpectomy | Chemotherapy | Relapse | Genes | Genetic research | Genetic aspects | Gene expression | Health aspects | Cancer | Diseases
Journal Article
European Urology, ISSN 0302-2838, 2013, Volume 65, Issue 6, pp. 1034 - 1043
Abstract Context Depending on the pathologic tumour stage, up to 60% of prostate cancer patients who undergo radical prostatectomy will develop biochemical...
Urology | Biochemical recurrence-free survival | Radiotherapy | Early salvage radiotherapy | Prostate cancer | ANDROGEN DEPRIVATION | EORTC TRIAL-22863 | BIOCHEMICAL RECURRENCE | survival | RANDOMIZED CLINICAL-TRIAL | LONG-TERM OUTCOMES | RISK | CANCER | UROLOGY & NEPHROLOGY | Biochemical recurrence-free | ADJUVANT RADIOTHERAPY | POSTOPERATIVE RADIATION-THERAPY | SINGLE-INSTITUTION EXPERIENCE | Disease-Free Survival | Neoplasm Recurrence, Local - radiotherapy | Prostatic Neoplasms - radiotherapy | Prostatic Neoplasms - surgery | Time Factors | Humans | Salvage Therapy | Prostatic Neoplasms - blood | Male | Prostatectomy | Neoplasm Recurrence, Local - blood | Prostate-Specific Antigen - blood | Nuclear radiation | Surgery
Urology | Biochemical recurrence-free survival | Radiotherapy | Early salvage radiotherapy | Prostate cancer | ANDROGEN DEPRIVATION | EORTC TRIAL-22863 | BIOCHEMICAL RECURRENCE | survival | RANDOMIZED CLINICAL-TRIAL | LONG-TERM OUTCOMES | RISK | CANCER | UROLOGY & NEPHROLOGY | Biochemical recurrence-free | ADJUVANT RADIOTHERAPY | POSTOPERATIVE RADIATION-THERAPY | SINGLE-INSTITUTION EXPERIENCE | Disease-Free Survival | Neoplasm Recurrence, Local - radiotherapy | Prostatic Neoplasms - radiotherapy | Prostatic Neoplasms - surgery | Time Factors | Humans | Salvage Therapy | Prostatic Neoplasms - blood | Male | Prostatectomy | Neoplasm Recurrence, Local - blood | Prostate-Specific Antigen - blood | Nuclear radiation | Surgery
Journal Article